PTGS2 and cholangiocarcinoma: We also retrospectively reviewed patients with mass-forming CCA (MF-CCA) to investigate the relationship of COX-2 expression with clinical characteristics and prognosis of CCA patients in an effort to re-evaluate the role of COX-2 inhibitors in CCA treatment.